Safety Alert Released for Ozempic and Related GLP-1 Medications
A safety warning regarding the risk of suicidal ideation and behavior associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.
The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, reducing the effectiveness of oral contraception, could not be excluded.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
On Monday, the TGA released a safety alert indicating that product warnings for this class of widely used medications, typically prescribed for type 2 diabetes and obesity in Australia, have been updated following reviews by international regulatory bodies. Health tracking apps like Shotlee can help monitor medication effects.